Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: A narrative review

Revista Portuguesa de Cardiologia

Volumn 28, Issue 10, 2009, Pages 1099-1119

  Miranda, Vasco P ^a   Rodrigues, Mariana J O ^b   Gonçalves, Francisco Rocha ^c   Nunes, José Pedro L ^c   Providência, Rui ^d  

^a Institute of Biomedical Sciences Abel Salazar   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c University of Porto   (Portugal)

^d NONE

Author keywords

Diabetes mellitus; Mortality; Myocardial infarction; Outcome; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PHENFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; TOLBUTAMIDE; VITAMIN;

ADD ON THERAPY; ANGINA PECTORIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLAUDICATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FOLLOW UP; FRACTURE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART RATE; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INTERVENTION STUDY; LACTIC ACIDOSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; STROKE; TRANSIENT ISCHEMIC ATTACK; ULCER; UNIVERSITY; WEIGHT; WEIGHT GAIN;

EID: 72949102653     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest 1975; 55: 454-461.
2. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8-13. (Pubitemid 9082394)
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med 1998; 339: 229-234. (Pubitemid 28350165)
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444. (Pubitemid 23046633)
5. Katz MH. Multivariable analysis. A practical guide for clinicians. 2nd edition. Cambridge University Press, Cambridge, 2006.
6. Goodarzi MO, Psaty BM. Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? JAMA 2008; 300: 2051-2053.
7. Meinert CL, Knatterud GL, Prout TE, Klimt CR (The University Group Diabetes Program). A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 Suppl: 789-830.
8. Knatterud GL, Klimt CR, Osborne RK, Meinert CL, Martin DB, Hawkins BS (The University Group Diabetes Program). A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 1975; 24 Suppl 1: 65-184.
9. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG (The University Group Diabetes Program). Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240:37-42.
10. Abraira C, Colwell JA, Nuttall F, Sawin F, Henderson W, et al. Cardiovascular events and correlates in the Veterans Affairs Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997; 157:181-188
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
12. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008; 359: 1577-1589.
14. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 358: 2545-2559.
15. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572
16. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
17. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393 (Pubitemid 36159355)
18. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-591. (Pubitemid 351214285)
19. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289. (Pubitemid 41416583)
20. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med 2006; 355: 2427-2443. (Pubitemid 44903747)
21. Home Pd, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 28-38. (Pubitemid 47026732)
22. Mazzone T, Meyer PM, Feinsein SB, Davidson MH, Kondos GT, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296: 2572-2581. (Pubitemid 44903861)
23. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008; 299: 1561-1573.
24. Nissen, SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
25. Diamond GA, Bax L, Kaul S. Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death. Ann Intern Med 2007; 147: 578-581. (Pubitemid 351664507)
26. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180-1188. (Pubitemid 47403104)
27. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA 2007; 298: 1189-1195. (Pubitemid 47403105)
28. Sasaki A, Uehara M, Horiuchi N, Hasegawa K, Shimizu T. A 15-year follow-up study of patients with non-insulin-dependent diabetes mellitus (NIDDM) in Osaka, Japan. Factors predictive of the prognosis of diabetic patients. Diabetes Res Clin Pract 1997; 36: 41-47
29. Bruno G, Merletti F, Boffetta P, Cavallo-Perin P, Bargero G, et al. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1999; 42: 297-301. (Pubitemid 29111435)
30. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
31. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005; 22: 497-502.
32. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 169-174.
33. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004; 20: 239-245. (Pubitemid 38714323)
34. Evans JMM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
35. Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 2007; 30: 1689-1693. (Pubitemid 47036337)
36. Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand A et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558-560. (Pubitemid 30322072)
37. Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, et al. Oral antidiabetic treatment in patients with coronary dis- ease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24: 151-158. (Pubitemid 32108625)
38. Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004 ; 20: 44-47. (Pubitemid 38196247)
39. Monami M, Marchionni N, Masotti G, Mannucci E. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. Int J Cardiol 2008; 126 : 247-251. (Pubitemid 351602106)
40. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-2643. (Pubitemid 350254955)
41. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Int Med 2008; 168: 2368-2375.
42. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26: 2983-2989. (Pubitemid 37339487)
43. Hartung DM, Touchette DR, Bultemeier NC, Haxby DG. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a Medicaid claims-based case-control study. Pharmacotherapy 2005; 25: 1329-1336.
44. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30: 2148-2153.
45. Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005; 22: 986-993. (Pubitemid 41025993)
46. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583-590. (Pubitemid 40216485)
47. Gu K, Cowie CC, Harris MI. Diabetes and Decline in Heart Disease Mortality in US Adults. JAMA 1999; 281: 1291-1297. (Pubitemid 29174480)
48. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, et al. Glycemic control and coronary heart disease risk in persons with and without diabetes. The Atherosclerosis Risk in Communities Study. Arch Int Med 2005; 165: 1910-1916.
49. Nunes JPL, Silva JC. Systemic correlates of angiographic coronary artery disease. PLos ONE 2009 4(1): e4322. doi:10.1371/joumal.pone.0004322.
50. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301. (Pubitemid 121000706)
51. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
52. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653. (Pubitemid 41817713)
53. Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract 2008; 82: 391-395.
54. Ashcroft FM, Cribble FM. Tissue-specific effects of sulfonylureas. Lessons from studies of cloned KATP channels. J Diabetes Complications 2000; 14: 192-196.
55. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000; 1006: 1305-1307.
56. Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, et al. MitoNEET is a uniquely folded 2Fe-2S outer mitochondrial membrane protein stabilized by pioglitazone. PNAS 2007; 104: 14342-14347.
57. Zhang H, Li Y, Fan Y, Wu J, Zhao B, et al. Klotho is a target gene of PPAR-Á. Kidney Int 2008; 74: 732-739.
58. Krumholz HM, Lee TH. Redefining quality - implications of recent clinical trials. N Engl J Med 2008; 358: 2537-2539. (Pubitemid 351831354)
59. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, et al. High fasting insulin concentrations appear to be an independent predictor of ischemic heart disease in men. N Engl J Med 1996; 334: 952-957.
60. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis. Endocr Rev 2006; 27: 242-259.
61. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737. (Pubitemid 39346675)
62. Nunes JPL. The risk factor association syndrome as a barisystemic syndrome: A view on obesity and the metabolic syndrome. Med Hypotheses 2007; 68: 541-545. (Pubitemid 46037980)